ORIGINAL ARTICLES. Clinical StudiesTreatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation1
Under an Elsevier user license
open archive
Keywords
disseminated intravascular coagulation
drotrecogin alfa (activated)
severe sepsis
Cited by (0)
- 1
Conflict of Interest/Financial Disclosure: Eli Lilly and Co. provided funding for this study. Jean‐Francois Dhainaut was an investigator in the PROWESS study and is a consultant for Eli Lilly and Co. Ville Pettilä has participated as an investigator in Eli Lilly and Co.‐sponsored clinical trials. Marcel Levi has participated as an investigator in Eli Lilly and Co.‐sponsored clinical trials and has been an invited speaker at conferences supported by Eli Lilly and Co. S. Betty Yan, David E. Joyce, Bruce Basson, John T. Brandt and David P. Sundin are employees and stockholders of Eli Lilly and Co.
Copyright © 2004 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.